Activin and Inhibin

JNJ-55308942 is a high-affinity, selective, brain-penetrant P2X7 functional antagonist (hP2X7: IC 50 =10 nM, K i =7.1 nM: rP2X7: IC 50 =15 nM, K i =2.9 nM). JNJ-55308942 is orally bioavailable, binds to brain P2X7 and blocks IL-1β release from adult

JNJ-55308942 is a high-affinity, selective, brain-penetrant P2X7 functional antagonist (hP2X7: IC 50 =10 nM, K i =7.1 nM: rP2X7: IC 50 =15 nM, K i =2.9 nM). JNJ-55308942 is orally bioavailable, binds to brain P2X7 and blocks IL-1β release from adult

JNJ-55308942 is a high-affinity, selective, brain-penetrant P2X7 functional antagonist (hP2X7: IC 50 =10 nM, K i =7.1 nM: rP2X7: IC 50 =15 nM, K i =2.9 nM). JNJ-55308942 is orally bioavailable, binds to brain P2X7 and blocks IL-1β release from adult

JNJ-55308942 is a high-affinity, selective, brain-penetrant P2X7 functional antagonist (hP2X7: IC 50 =10 nM, K i =7.1 nM: rP2X7: IC 50 =15 nM, K i =2.9 nM). JNJ-55308942 is orally bioavailable, binds to brain P2X7 and blocks IL-1β release from adult

JNJ-9350 is an inhibitor of spermine oxidase ( SMOX ) with an IC 50 value of 0.01 μM. JNJ-9350 also inhibits polyamine oxidase ( PAO ) with an IC 50 value of 0.79 μM. JNJ-9350 can be used for the research of cancerIn VitroJNJ-9350 (0-100 μM) shows

JNJ4796 is an oral active fusion inhibitor of influenza virus , neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA) -mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs)In VitroLike

JNJ4796 is an oral active fusion inhibitor of influenza virus , neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA) -mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs)In VitroLike

JNJ4796 is an oral active fusion inhibitor of influenza virus , neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA) -mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs)In VitroLike

JO146 is a Chlamydia trachomatis high temperature requirement A ( CtHtrA ) protease inhibitor with IC 50 s of 21.86 and 1.15 μM for CtHtrA and human neutrophil elastase (HNE), respectively. JO146 can be used to inhibits bacterial

JO146 is a Chlamydia trachomatis high temperature requirement A ( CtHtrA ) protease inhibitor with IC 50 s of 21.86 and 1.15 μM for CtHtrA and human neutrophil elastase (HNE), respectively. JO146 can be used to inhibits bacterial

JO146 is a Chlamydia trachomatis high temperature requirement A ( CtHtrA ) protease inhibitor with IC 50 s of 21.86 and 1.15 μM for CtHtrA and human neutrophil elastase (HNE), respectively. JO146 can be used to inhibits bacterial

JO146 is a Chlamydia trachomatis high temperature requirement A ( CtHtrA ) protease inhibitor with IC 50 s of 21.86 and 1.15 μM for CtHtrA and human neutrophil elastase (HNE), respectively. JO146 can be used to inhibits bacterial